ChiCTR2200057754Not yet recruiting
Untitled Trial
A real-world multicenter retrospective prospective clinical study of the efficacy and safety of Ensartinib capsules in patients with advanced ALK-positive non-small cell lung cancer
BEIJING TIANTAN HOSPITAL,CAPTIAL MEDICAL UNIVERSITYPhase 4Chinese Clinical Trial Registry
Study focus
- Disease/Condition
- lung cancer
Sponsor & location
- Primary sponsor
- BEIJING TIANTAN HOSPITAL,CAPTIAL MEDICAL UNIVERSITY
- Funder
- self-funds
- Location
- China
Timeline & enrollment
- Phase
- Phase 4
- Start date
- N/A
- End date
- Oct 01, 2023
ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2200057754
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2200057754 through Pure Global AI's free database. This Phase 4 trial is sponsored by BEIJING TIANTAN HOSPITAL,CAPTIAL MEDICAL UNIVERSITY and is currently Not yet recruiting. The study focuses on lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.